This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
He explains the key considerations for choosing a specialtypharmacy network design, selecting the right pharmacy partners, and establishing patient services HUBs. To learn more, download PANTHERxs latest white paper and SP decision-support resource: Selecting the Right SpecialtyPharmacy Partner for a Successful Launch.
Drug Channels Institute’s (DCI’s) latest analysis finds that participants in the specialtypharmacy market continue to get more diverse—although revenues remain highly concentrated. Read on for DCI’s latest overview of the 2023 marketplace and revenues of the biggest market participants, along with key specialtypharmacy trends.
Hospitals and health systems are rapidly expanding their internal specialtypharmacies—and they’re using questionable tactics to boost revenues and profits. Nearly two-thirds of the larger health system specialtypharmacies operate as the exclusive pharmacy within self-insured health systems’ networks.
specialtypharmacies—via white, brown, and clear bagging—continue to displace buy-and-bill distribution channels for provider-administered oncology drugs. The battle for the specialty patient pits hospitals against insurers—and their respective specialtypharmacies. Coming out of the pandemic (maybe?),
Two weeks ago, Paula and I had the pleasure of attending Asembia’s 2022 SpecialtyPharmacy Summit at the wonderful Wynn Las Vegas. I offer reflections on my keynote session with Scott Gottlieb, share my experiences during the featured session, and highlight three crucial specialty industry trends. d/b/a Drug Channels Institute.
For 2022, pharmacy benefits managers (PBMs) and insurers expanded their dominance over specialty dispensing, though both hospitals and physician practices are growing their share of the market. The top three PBM-owned specialtypharmacies accounted for nearly two-thirds of prescription revenues from pharmacy-dispensed specialty drugs.
Significant volume will shift to the larger players, as Centene plots its exit, Walgreens’ specialtypharmacy business collapses, and manufacturers’ 340B contract pharmacy restrictions continue. This week, I’m attending Asembia’s SpecialtyPharmacy Summit. d/b/a Drug Channels Institute.
Significant volume will shift to the larger players, as Centene plots its exit, Walgreens’ specialtypharmacy business collapses, and manufacturers’ 340B contract pharmacy restrictions continue. This week, I’m attending Asembia’s SpecialtyPharmacy Summit. d/b/a Drug Channels Institute.
Jayne discusses changes in the life science and specialtypharmacy industries since the COVID-19 pandemic began. She highlights three key trends that pharma companies, plan sponsors, and others will consider as we head to the upcoming Asembia SpecialtyPharmacy Summit (October 26 to 29 in Las Vegas).
Informa Connect’s Hub and SpecialtyPharmacy Models East. June 28-30, 2022 | Sheraton Parsippany | Parsippany, NJ www.informaconnect.com/hub-specialty-pharmacy. For 2022 only, Hub and SpecialtyPharmacy Models and PAP – Patient Assistance & Access Programs are under the same roof.
Asembia’s SpecialtyPharmacy Summit 2022. Asembia's SpecialtyPharmacy Summit 2022 is back! This is a must-attend event for anyone connected to specialtypharmacy. Plus, Doug Long from IQVIA and I will again lead the Featured Session, titled The SpecialtyPharmacy Industry Update and Outlook.
Last week, we documented the substantial concentration of dispensing revenues for specialty drugs. See The Top 15 SpecialtyPharmacies of 2023: Market Shares and Revenues at the Biggest PBMs, Health Plans, and Independents. Today, we examine how manufacturers’ specialty networks contribute to this concentration.
What is SpecialtyPharmacy? I have been a pharmacist for more than 25 years and since I started working within the specialtypharmacy arena in 2006, it has changed dramatically over the years. In 2006, not many people had previously heard of specialtypharmacy, although the practice has been around since the 1970s.
Last week, we documented the substantial concentration of dispensing revenues for specialty drugs. See The Top 15 SpecialtyPharmacies of 2023: Market Shares and Revenues at the Biggest PBMs, Health Plans, and Independents. Today, we examine how manufacturers’ specialty networks contribute to this concentration.
Today’s guest post comes from Megan Marchal, Director of SpecialtyPharmacy Strategy at CoverMyMeds. Megan discusses the access and affordability challenges faced by specialty therapy patients. Click here to sign up for CoverMyMeds’ Asembia SpecialtyPharmacy Summit recaps. Read on for Megan’s insights.
In this issue: The State of SpecialtyPharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble Reconsidering Amazon P.S. Please join the nearly 13,000 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter. Happy Thanksgiving, everyone!
For updated data on hospital-owned specialtypharmacies, see Chapter 3 of DCI's new 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. As many of you know, hospitals and health systems have emerged as significant participants in the specialtypharmacy industry.
In this issue: The State of SpecialtyPharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon P.S. Please join me for my upcoming live video webinar, Drug Channels Outlook 2022 , on December 17, 2021, from 12:00 p.m.
This Valentine's Day, what could be more romantic than a deep dive into the relationships between manufacturers of specialty drugs and the pharmacies they choose for their limited and exclusive specialtypharmacy networks. As you’ll see, a typical network contains only five specialtypharmacies.
Below, we update our exclusive analysis of the biggest specialtypharmacies within 340B. The four largest specialtypharmacies are owned by CVS Health, Cigna’s Express Scripts business, UnitedHealth Group’s OptumRx business, and Walgreens Boots Alliance/Prime Therapeutics. d/b/a Drug Channels Institute.
Will COVID-19 trigger long-term share gains for specialtypharmacies as suppliers to hospitals and physician offices? Before the pandemic, specialtypharmacies—via white, brown, and clear bagging—had already displaced buy-and-bill distribution channels for a substantial chunk of provider-administered specialty drugs.
However, Walgreens disclosed that it also generates about $16 billion in specialty revenues from its retail pharmacies and nearly 300 community-based specialtypharmacy locations. See Walgreens Launches Gene and Cell Services as Part of Newly Integrated Walgreens SpecialtyPharmacy Business.
In this issue: The State of SpecialtyPharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon Plus, the FDA preps you for Thursday with a regulatory soup review. Happy Thanksgiving, everyone! to 1:30 p.m.
Will COVID-19 trigger long-term share gains for specialtypharmacies as suppliers to hospitals and physician offices? Before the pandemic, specialtypharmacies—via white, brown, and clear bagging—had already displaced buy-and-bill distribution channels for a substantial chunk of provider-administered specialty drugs.
In Drug Channels Institute's list of the top 15 pharmacies of 2019 , we show that many of the largest U.S. pharmacies are now central-fill mail and specialtypharmacies operated by PBMs and insurers. I see upside for specialtypharmacies in the aftermath of the pandemic. d/b/a Drug Channels Institute.
National Association of SpecialtyPharmacy (NASP) 2021 Annual Meeting & Expo. The National Association of SpecialtyPharmacy (NASP) returns to Washington, D.C. on September 27-30 for the National Association of SpecialtyPharmacy (NASP) 2021 Annual Meeting & Expo. d/b/a Drug Channels Institute.
Let’s turn up the heat with these sizzling news bites straight from the Drug Channels grill: SaveonSP gets sued Thoughts on the Medicaid accumulator rule opinion CVS buys AmerisourceBergen’s specialtypharmacy Fresh data on hospitals’ cancer drug profiteering Plus, Dr. Glaucomflecken explains Aetna’s prior authorization policies.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content